STAT

What if we’re no longer afraid of Ebola?

If we're no longer afraid of Ebola, we might have a problem.
A Ebola medical response worker checks her protective equipment in front of a mirror at the Bwera General Hospital in western Uganda.

In late July of 2014, I received an email from someone who had just started her medical residency. Why, she wanted to know, was the United States allowing American Dr. Kent Brantly to return to be treated for Ebola, which he had contracted while caring for patients in the exploding West African outbreak?

Why bring it here, she asked, expressing deep concern that his return could create an opportunity for Ebola to escape from Atlanta’s Emory University Hospital — where he was to be cared for in a special high containment unit — and spread on a continent where the virus is not typically found.

The email was a testament to a palpable sense of fear around in the Democratic Republic of the Congo isn’t getting much attention or much funding.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.
STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.

Related Books & Audiobooks